Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Psyence Biomedical ( (PBM) ) is now available.
Psyence Biomedical Ltd. has filed its unaudited interim financial statements for the periods ending September 30, 2024, and 2023, alongside its updated audited financial statements for fiscal years ending March 31, 2024, and 2023. The update includes adjustments for a reverse stock split at a ratio of 75-to-1, effective November 26, 2024. This adjustment, made to reflect changes in share and per-share amounts, impacts stakeholders by altering the company’s financial disclosures without modifying the previously filed audited statements.
More about Psyence Biomedical
Psyence Biomedical Ltd., headquartered in Toronto, Ontario, operates within the biomedical industry. The company is involved in the development and delivery of innovative medical treatments, focusing primarily on leveraging the therapeutic potential of psychedelic compounds.
YTD Price Performance: -17.31%
Average Trading Volume: 2,559,445
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.89M
See more insights into PBM stock on TipRanks’ Stock Analysis page.
